The nonavalent HPV vaccine is a papillomavirus vaccine which is unique of its kind. The nonavalent vaccine offers the chance to broaden HPV vaccine prevention, giving a greater protection against HPV-related diseases, in both sexes.
To date, it is the human HPV vaccine with the widest cover: there is no other vaccine that protects against 9 types of HPV (6, 11, 16, 18, 31, 33, 45, 52 and 58).
The nonavalent HPV vaccine is the best means of prevention currently available for HPV-related disease in both sexes: its implementation is consistent with the new public health objective for HPV vaccination to offer adolescents of both sexes maximum protection against all HPV-related diseases which can be directly prevented by vaccination, as expressed in the new National Prevention Plan 2017-2019.
Broader vaccination with the new nonavalent HPV vaccine will enable prevention of the development of cancer in both sexes and precancerous lesions of the cervix, vulva, vagina, anus and the external benign ano-genital lesions (genital warts) caused by the 9 HPV types present in the vaccine. The nonavalent vaccine has shown, in the numerous trials during its clinical development, clinical efficacy ranging from 96 to 100% in the prevention of such lesions. The protection provided by the nonavalent vaccine will lead to a substantial reduction of HPV-related diseases.
